行情

CYTK

CYTK

细胞动力
NASDAQ

实时行情|Nasdaq Last Sale

9.51
+0.02
+0.21%
盘后: 9.70 +0.19 +2.00% 16:18 12/11 EST
开盘
9.51
昨收
9.49
最高
9.67
最低
9.43
成交量
95.88万
成交额
--
52周最高
14.94
52周最低
5.75
市值
5.62亿
市盈率(TTM)
-4.5699
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CYTK 新闻

  • Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy?
  • Insider Monkey.1天前
  • World's largest biotech company to move up to BioMed's big South City project
  • American City Business Journals.2天前
  • Cytokinetics (CYTK) Investor Presentation - Slideshow
  • Seeking Alpha - Article.6天前
  • Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND
  • GlobeNewswire.6天前

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

CYTK 简况

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.
展开

Webull提供Cytokinetics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。